TREATMENT OF RHEUMATOID ARTHRITIS WITH ORAL BOVINE TYPE II CARTILAGE

用牛口腔 II 型软骨治疗类风湿性关节炎

• 批准号: 6116823
• 负责人: ARNOLD E POSTLETHWAITE
• 金额: --
• 依托单位: UNIVERSITY OF TENNESSEE HEALTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 1999-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6116823
• 关键词: animal extract; antiinflammatory agents; clinical research; clinical trials; collagen; drug screening /evaluation; human subject; human therapy evaluation; immunopathology chemotherapy; longitudinal human study; oral administration; outcomes research; rheumatoid arthritis; skeletal disorder chemotherapy

The goal of this study is to test the hypothesis that orally administered soluble bovine type II collagen will decrease clinical signs and symptoms of RA and laboratory parameters characteristic of RA activity in patients whose disease is not controlled by DMARDs and/or nonsteroidal anti- inflammatory drug (NSAID) therapy. This is a double-blind, placebo- controlled trial involving 250 patients with active RA. Follow-up visits to assess any long-term effects will be made after another 6 months.

本研究的目的是检验口服给药 可溶性牛II型胶原蛋白将减少临床体征和症状 RA和RA活动特征的实验室参数 其疾病未被DMARD和/或非甾体抗- 抗炎药（NSAID）治疗。这是一个双盲安慰剂 对照试验涉及250例活动性RA患者。 随访访视 评估任何长期影响将在另一个6个月后进行。